Inhibition of N‐glycosylation by glucosamine hydrochloride inhibits TGF‐β1‐induced LOXL2 secretion

Abstract

AbstractKidney fibrosis is closely associated with the progression of chronic kidney disease (CKD). Furthermore, copper‐containing secretory amine oxidases, such as lysyl oxidase (LOX) and LOX‐like 1–4 (LOXL1–4), play pivotal roles in the regulation of extracellular components and facilitate fibrosis. In this study, we investigated the regulation of LOX enzymes in human tubular epithelial HK2 cells to help clarify the role of LOX enzymes in kidney fibrosis. Among 5 LOX enzymes, LOXL2 expression is abundantly expressed in HK2 cells. LOX enzymes inhibitor, β‐aminopropionitrile, suppressed transforming growth factor‐β1 (TGF‐β1)‐promoted epithelial‐to‐mesenchymal transition processes in HK2 cells, indicating that LOX enzymes are involved in TGF‐β1‐mediated fibrotic processes. Recent studies suggest that LOX enzymes are secreted into the extracellular spaces by exosomes and promote fibrotic processes. Similar to the previous reports, we observed that exosomes secreted from HK2 cells carry LOXL2 into the extracellular spaces. Furthermore, we determined that N‐glycosylation on the asparagine residues plays a key role in LOXL2 secretion. Amino acid mutations in three asparagine residues, which can be glycosylated, suppressed the secretion of mutated LOXL2. Moreover, N‐acetylglucosaminyltransferase 5, an enzyme used for the biosynthesis of β1,6N‐acetylglucosamine‐branched N‐glycans, participated in LOXL2 secretion, and the N‐glycosylation inhibitor, glucosamine hydrochloride (GS), inhibited TGF‐β1‐mediated LOXL2 secretion and fibrotic processes. Overall, TGF‐β1 promotes LOXL2 secretion and may participate in kidney fibrosis. Our results provide novel insight into the antifibrotic properties of GS that contribute to the inhibition of CKD progression.